Health authorities are monitoring a fast spreading Ebola outbreak in the Democratic Republic of Congo. The outbreak has already caused close to 250 deaths.
More than 1,000 suspected infections have been reported in DR Congo. Uganda has confirmed nine related cases across the border.
Experts warn that delayed detection in a conflict affected region has allowed the virus to spread quickly. Limited healthcare access has made control efforts more difficult.
Health groups fear the outbreak could grow to a scale similar to the major West African crisis between 2014 and 2016, which infected nearly 29,000 people and caused over 11,000 deaths.
Vaccine Development Efforts Accelerate
Three separate vaccine projects are now in progress to respond to the outbreak.
The International Aids Vaccine Initiative is leading one program. It warns that the outbreak could become one of the most severe ever recorded.
The University of Oxford is also working on a vaccine, along with Moderna, focusing on protection against the Bundibugyo strain.
The Coalition for Epidemic Preparedness Innovations is funding these projects and urges rapid action, stressing that each day matters in controlling the spread.
Dr Mark Feinberg from the International Aids Vaccine Initiative says the outbreak may reach or exceed the severity of past epidemics if responses remain slow. He emphasizes that vaccine development and other countermeasures are urgent priorities.
Why the Bundibugyo Strain Is a Challenge
Ebola has six known species, but only three usually cause large outbreaks.
A vaccine already exists for the Zaire strain, which is the most common. However, the current outbreak is caused by the Bundibugyo strain, which is rare and has been detected only a few times before.
No approved vaccine currently exists for this strain.
Researchers are now adapting an existing Zaire based vaccine to target Bundibugyo.
Early tests in animals show strong results. The experimental vaccine helped activate the immune system quickly and provided near complete protection in monkeys.
Scientific Progress in Early Testing
Preclinical studies suggest that the modified vaccine can trigger a strong immune response.
Researchers report close to full protection in animal trials, which supports further development for human testing.
